30 closest matches · ranked by relevance
Acute Myeloid Leukemia (AML)
Primary: Event Free Survival (EFS) — 5.98; 5.88 Months
Acute Myeloid Leukemia
Primary: Percentage of Patients With Adverse Events (AEs), Grade 3 & 4 AEs, Serious Adverse Events (SAEs), AEs Leading to Discontinuation, and Deaths up to 24 Months (M24)…
Acute Myeloid Leukemia
Primary: Number of Patients Who Relapsed — 5; 2; 0; 1 Participants
Acute Myeloid Leukemia
Primary: Proportion of Participants With Relapse Free Survival (RFS) up to 18 Months Post Transplant (Full Analysis Set) by Kaplan-Meier Analysis — 0.93; 0.93; 0.80; 0.93…
Leukemia, Myeloid, Acute
Primary: Composite Complete Remission (CRc) Rate After Treatment With Quizartinib in Japanese Participants With FLT3-ITD Positive Relapsed or Refractory AML — 56.5; 33.3; 53.8…
Acute Myeloid Leukemia
Primary: Relapse-free Survival (RFS) — NA; NA months — p=0.0518
Leukemia, Acute Myeloid (AML)
Primary: Duration of Overall Survival (OS) — 9.3; 5.6 Months — p=0.0004
Acute Myeloid Leukemia
Primary: Percentage of Safety Events (Part 1, Japan Only) — 5; 0 Participants
Acute Myeloid Leukemia
Primary: Response Rate of Crenolanib Besylate Combination Therapy — 2; 0; 3; 1 Participants
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Primary: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 2 Participants
Non-small Cell Lung Cancer (NSCLC)
Primary: Progression-Free Survival — 14 Participants
Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Primary: Overall Response Rate — 5; 2; 3; 1 Participants
Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies
Primary: Response Rate of Patients Receiving Crenolanib Therapy — 8; 3; 4; 1 Participants
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Primary: Relapse-free Survival (RFS) Per Independent Review Committee (IRC) Adjudication — 24.02; 15.84 Months — p=0.163
Acute Myeloid Leukemia (AML) · Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Primary: Overall Survival (OS) — 9.82; 9.23; 5.24 months — p=0.523
Leukemia
Primary: Participants With a Response CR + PR + CRi — 4; 1; 4 Participants
Acute Myeloid Leukemia · Myelodysplastic Syndromes
Primary: Number of Participants With Best Clinical Response (Core) — 0 Participants
Acute Myeloid Leukemia · Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Treatment-Emergent Treatment Related Adverse Events Following Oral Administration of Quizartinib in Participants With Relapsed or Refractory…
Tumor Pathway Activations Inhibited by Dovitinib
Primary: Clinical Benefit Rate (CBR) — 0; 1; 10; 11 number of participants
Chronic Myelogenous Leukemia - Chronic Phase
Primary: Number of Participants With Adverse Events and Serious Adverse Events for Cohorts A and B up to 24 Weeks — 23; 26; 1; 3 Participants
Gastrointestinal Stromal Tumors
Primary: Disease Control Rate (DCR; OR + Stable Disease) — 13 Percentage of participants
Myeloproliferative Neoplasms
Primary: Number of Participants With Hematological Response, as Measured by Any One or More of the Following Response Assessments: IWG-MDS and IWG-MF Criteria as Accurate and…
Acute Myeloid Leukemia · Leukemia
Primary: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia — 31.9; 15.1 months — p=0.0324
AML
Primary: Overall Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy — 27.0; 20.4 weeks — p=0.0185
Newly Diagnosed AML With FLT3 Activating Mutations
Primary: Clinical Response to Crenolanib With Standard Induction Chemotherapy — 26; 12; 38; 22 Participants
Myelofibrosis · Chronic Myelomonocytic Leukemia
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…
Leukemia
Primary: Overall Survival (OS) — 45.9 Percentage of participants
Recurrent Acute Leukemia of Ambiguous Lineage · Recurrent Acute Lymphoblastic Leukemia · Recurrent Acute Myeloid Leukemia
Primary: Percentage of Patients we Are Able to Test and Initiate Treatment Within a 21 Day Period — 21 Participants
Acute Myeloid Leukemia
Primary: Number of Participants With Complete Remission With or Without Incomplete Platelet Recovery — 1 Participants